All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

EHA 2018 | Venetoclax safety and efficacy in patients with previously treated WM

Jul 21, 2018

Bookmark this article

On Saturday 16th June an oral abstract session took place at the 23rd Congress of the European Hematology Association (EHA). Abstract S854 was presented by Jorge Castillo, Dana-Farber Cancer Institute, Boston, US, on the phase II study outcomes of venetoclax in patients with previously treated Waldenström macroglobulinemia (WM).

Study Overview

  • Eligible patients included in the study (N = 30) were treated with 200mg venetoclax orally once daily for a week up to 800mg once daily until disease progression or for a maximum of 2 years
  • Median follow-up was 11 months 

Key Findings

  • The baseline median serum IgM was 3,543 mg/dl (range 642-7,970 mg/dl) and at 6 months, the median serum IgM had declined to 1,640 mg/dl (range 49-5,220 mg/dl)
  • The overall response rate was of 87% and the major response rate was 74%
  • 5 patients (17%) achieved very good partial response (VGPR) and a partial response was seen in 17 patients (57%)
  • The major response rate was not statistically different based on relapsed or refractory disease, prior ibrutinib exposure or CXCR4 mutation status
  • VGPR rate at best response was lower in patients with prior ibrutinib exposure (7% vs 27%), and in patients with CXCR4MUT compared with CXCR4WT (7% vs 29%)
  • The most frequent Adverse Events (AEs) Grade ≥3 included: neutropenia (n = 9), anemia (n = 2) and upper respiratory infection (n = 1)

Dr Castillo concluded his talk by stating that the results of this study demonstrated that the use of venetoclax was safe and effective in patients with previously treated WM. It also showed venetoclax efficacy in patients with CXCR4 mutations and patients with previous exposure to BTK inhibitors.

Expert Opinion

  1. Castillo J. Prospective phase II study of venetoclax (VEN) in patients (pts) with previously treated Waldenström macroglobulinemia (WM). Abstract S854. 23rd Congress of EHA, Stockholm, Sweden

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

Which treatment do you select for patients with follicular lymphoma after multiple relapses?
0 votes - 6 days left ...


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox